DE10059930A1 - Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore - Google Patents

Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore

Info

Publication number
DE10059930A1
DE10059930A1 DE2000159930 DE10059930A DE10059930A1 DE 10059930 A1 DE10059930 A1 DE 10059930A1 DE 2000159930 DE2000159930 DE 2000159930 DE 10059930 A DE10059930 A DE 10059930A DE 10059930 A1 DE10059930 A1 DE 10059930A1
Authority
DE
Germany
Prior art keywords
antibodies
ids
human
neuroblastoma
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE2000159930
Other languages
German (de)
English (en)
Inventor
Martina Uttenreuther-Fischer
Joerg Krueger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FISCHER, PETER, DR., 88400 BIBERACH, DE
UTTENREUTHER-FISCHER, MARTINA, DR., 88400 BIBE, DE
Original Assignee
UTTENREUTHER FISCHER MARTINA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UTTENREUTHER FISCHER MARTINA filed Critical UTTENREUTHER FISCHER MARTINA
Priority to DE2000159930 priority Critical patent/DE10059930A1/de
Priority to PCT/DE2001/004359 priority patent/WO2002087611A2/de
Publication of DE10059930A1 publication Critical patent/DE10059930A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE2000159930 2000-11-23 2000-11-23 Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore Withdrawn DE10059930A1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE2000159930 DE10059930A1 (de) 2000-11-23 2000-11-23 Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
PCT/DE2001/004359 WO2002087611A2 (de) 2000-11-23 2001-11-22 Mittel humanen ursprungs zur vakzination gegen gd2-positive tumore

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2000159930 DE10059930A1 (de) 2000-11-23 2000-11-23 Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore

Publications (1)

Publication Number Publication Date
DE10059930A1 true DE10059930A1 (de) 2002-05-29

Family

ID=7665547

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2000159930 Withdrawn DE10059930A1 (de) 2000-11-23 2000-11-23 Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore

Country Status (2)

Country Link
DE (1) DE10059930A1 (en18)
WO (1) WO2002087611A2 (en18)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091655A2 (en) * 2003-04-17 2004-10-28 Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag Immunogenic recombinant antibody
DE102011054413A1 (de) * 2011-10-12 2013-04-18 Ernst-Moritz-Arndt-Universität Greifswald Monoklonaler anti-Idiotyp-Antikörper Ganglidiomab
WO2015187811A3 (en) * 2014-06-04 2016-01-28 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN116769723B (zh) * 2023-08-09 2023-11-03 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
EP1000082A2 (en) * 1997-07-08 2000-05-17 Novopharm Biotech, Inc. Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091655A2 (en) * 2003-04-17 2004-10-28 Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag Immunogenic recombinant antibody
WO2004091655A3 (en) * 2003-04-17 2005-02-17 Igeneon Krebs Immuntherapie Immunogenic recombinant antibody
EP2322214A1 (en) * 2003-04-17 2011-05-18 Altropus Gmbh Immunogenic recombinant antibody
US8034338B2 (en) 2003-04-17 2011-10-11 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Immunogenic recombinant antibody
DE102011054413A1 (de) * 2011-10-12 2013-04-18 Ernst-Moritz-Arndt-Universität Greifswald Monoklonaler anti-Idiotyp-Antikörper Ganglidiomab
WO2013053694A1 (de) * 2011-10-12 2013-04-18 Ernst-Moritz-Arndt-Universität Greifswald Monoklonaler anti-idiotyp-antikörper ganglidiomab
WO2015187811A3 (en) * 2014-06-04 2016-01-28 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
US10906988B2 (en) 2014-06-04 2021-02-02 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
US11760809B2 (en) 2014-06-04 2023-09-19 BioNTech SE Human monoclonal antibodies to ganglioside GD2

Also Published As

Publication number Publication date
WO2002087611B1 (de) 2004-03-04
WO2002087611A3 (de) 2003-07-31
WO2002087611A2 (de) 2002-11-07

Similar Documents

Publication Publication Date Title
DE69434475T2 (de) Impfstoff gegen prostatakrebs
EP1115427B1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
DE69635843T2 (de) Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung
DE69605181T3 (de) Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
EP0826696B1 (de) Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
DE69626423T2 (de) Verfahren und zusammensetzung zum rekonformieren multiepitopischer antigene zum anregen einer immunantwort
DE69927262T2 (de) Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
CN105999293B (zh) Cd37结合分子及其免疫缀合物
DE60018761T2 (de) Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
AU640863B2 (en) Methods and substances for recruiting therapeutic agents to solid tissues
WO2000073430A2 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
EP0696456A2 (de) Kombination von Nekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Therapie von Tumoren und entzündlichen Erkrankungen
EP1140168B1 (de) Verwendung von antikörpern zur vakzinierung gegen krebs
DE602004003689T2 (de) Krebserkrankungen modifizierende antikörper
EP1229936B1 (de) Verwendung von anti-idiotypischen antikörpern als impfstoffe gegen krebs
DE10059930A1 (de) Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
EP1820514A2 (en) Therapeutic compositions that produce an immune response by altering the antigen
AT500650B1 (de) Immunogener rekombinanter antikörper
DE10296942T5 (de) Therapeutische Zusammensetzung, welche die Immunitätsreaktion verändert
DE60206731T2 (de) Polypeptide, die fähig sind, an CD64 zu binden und die ein oder mehrere Heterologe T-Zellenpitope enthalten, und deren Verwendung
DE69334036T2 (de) Hybridom und humanisierter momoklonaler Anti-KC-4-Antikörper, dafür kodierende DNA und RNA, Kit und diagnostische Verfahren
EP0825256B1 (de) Hybridzelle und deren Verwendung zur Herstellung eines Arzneimittels zur Induktion einer Tumorimmunität
WO2001081423A1 (de) Antikörper gegen natives gp96, deren herstellung und verwendung
AT500647A1 (de) Verwendung eines impfstoffes
EP1287831B1 (de) Antigen-Mimotope und Vakzine gegen Krebserkrankungen

Legal Events

Date Code Title Description
8181 Inventor (new situation)

Free format text: FISCHER, PETER, DR., 13505 BERLIN, DE KRUEGER, JOERG, 10965 BERLIN, DE UTTENREUTHER-FISCHER, MARTINA, DR., 13505 BERLIN, DE

8127 New person/name/address of the applicant

Owner name: FISCHER, PETER, DR., 88400 BIBERACH, DE

Owner name: UTTENREUTHER-FISCHER, MARTINA, DR., 88400 BIBE, DE

8141 Disposal/no request for examination